Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes

Drug Metabolism and Disposition

Volumn 29, Issue 6, 2001, Pages 887-890

  Yanagihara, Yoshitsugu ^a   Kariya, Satoru ^a   Ohtani, Michiteru ^a   Uchino, Katsuyoshi ^a   Aoyama, Takao ^b   Yamamura, Yoshikazu ^b   Iga, Tatsuji ^b  

^a Tokyo Postal Services Agency Hospital   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLOSPORIN A; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; KETAMINE; N DEMETHYLASE; ORPHENADRINE; SULFAPHENAZOLE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DEMETHYLATION; DRUG EXCRETION; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER MICROSOME; LYMPHOBLASTOID CELL; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KETAMINE; METHYLATION; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING;

EID: 0035010954     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Chang T, Savory A, Albin M, Goulet R and Glazko AJ (1970) Metabolic disposition of tritium-labelled ketamine. Clin Res 18:597.
2. Chang TKH, Weber GF, Crespi CL and Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53:5629-5637.
3. Chang TKH, Yu L, Maurel P and Waxman DJ (1997) Enhanced cyclophosphamide and ifosphamide activation in primary human hepatocyte cultures: response to cytochrome P-450 induces and autoinduction by oxazaphosphorines. Cancer Res 57:1946-1954.
4. Chen TL, Ueng TH, Chen SH, Lee PH, Fan SZ and Liu CC (1995) Human cytochrome P450 mono-oxygenase system is suppressed by propofol. Br J Anaesth 74:558-562.
5. Gantenbein M, Abat C, Attolini L, Pisano P, Emperaire N and Bruguerolle B (1997) Ketamine effects on bupivacaine local anaesthetic activity and pharmacokinetics of bupivacaine in mice. Life Sci 61:2027-2033.
6. Kharasch ED and Labroo R (1992) Metabolism of ketamine stereoisomers by human liver microsomes, Anesthesiology 77:1201-1207.
7. Lo JN and Cumming JF (1975) Interaction between sedative premedicants and ketamine in man and in isolated perfused rat livers. Anesthesiology 43:307-312.
8. Loch JM, Potter J and Bachmann KA (1995) The influence of anesthetic agents on rat hepatic cytochromes P450 in vivo. Pharmacology 50:146-153.
9. Mathisen LC, Skjelbred P, Skoglund LA and Øye I (1995) Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain 61:215-220.
10. Newton DJ, Wang RW and Lu AYH (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
11. Reich DL and Silvay G (1989) Ketamine: an update on the first twenty-five year of clinical experience. Can J Anaesth 36:186-197.
12. Shimoyama M, Shimoyama N, Gorman AL, Elliott KJ and Inturrisi CE (1999) Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine. Pain 81:85-93.
13. White PF, Way WL and Trevor AJ (1982) Ketamine - its pharmacology and therapeutic uses. Anesthesiology 56:119-136.
14. Woolf TF and Adams JD (1987) Biotransformation of ketamine, (Z)-6-hydroxyketamine, and (E)-6-hydroxyketamine by rat, rabbit, and human liver microsomal preparations. Xenobiotica 17:839-847.
15. Yamaoka K, Tanigawara Y. Nakagawa T and Uno T (1981) A pharmacokinetics analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879-885.
16. Yanagihara Y, Ohtani M, Kariya S, Uchino K, Aoyama T, Yamamura Y and Iga T (2000) Stereoselective high-performance liquid chromatographic (HPLC) determination of ketamine and its active metabolite, norketamine, in human plasma. J Chromatogr 746:227-231.